<DOC>
	<DOCNO>NCT02980536</DOCNO>
	<brief_summary>The purpose study evaluate mutation pattern epidermal growth factor receptor ( EGFR ) TKI target gene TKI treatment advance NSCLC patient liquid biopsy .</brief_summary>
	<brief_title>cSMART Liquid Biopsy Dynamic Monitor NSCLC Patients Inner-Mongolia China</brief_title>
	<detailed_description>In study , 200 advance NSCLC patient recruit . All patient receive biopsy genotype assay Circulating Single-Molecule Amplification Resequencing Technology ( cSMART ) liquid biopsy . patient carry EGFR activate mutation TKI target activate mutation receive TKI treatment . During TKI treatment , every patient take liquid biopsy assay monitor mutation status . study end patient progressive disease ( PD ) target lesion</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>NSCLC adenocarcinoma patient confirm pathologist Initial , nonoperative patient stage III &amp; IV adenocarcinoma Older 18 year old Subjects major organ dysfunction . In detail , Liver Function : TBiL≤1.5 ULN ( Upper Limit Normal ) ; Serum GPT ( GlutamatePyruvate Transaminase ) : ≤2 ULN , Renal Function : ScR≤1.2 ULN ; BUN≤1.2 ULN , BM ( Bone Marrow ) Reserve : WBC ( White Blood cell Count ) ≥4.0×e9/L ; ANC≥2.0×e9/L，PLT≥100×e9/L，HGB≥100g/L . PS ( Performance Status ) Score : le 2 , Expected Survival Time : More 3 month ; Have clear measurable tumor lesion lung , RIEST . Without severe drug allergy Patients participate trail must sign informed consent Patients brain metases related syndrome Patients bone metases related complication Patients cognitive disorder Patients major organ dysfunction severe cardiopathy include congestive heartfailure , uncontrolled arrhythmia , angina long term treatment , VHD ( Valvular Heart Disease ) , myocardial infraction , RHTN ( Resistant Hypertension ) . Patients severe complication exclude researcher . Patients allergy TKI trail . Patients participate trails antitumor treatment Patients receive radiotherapy site curative effect observation Patients receive allogenic blood transfusion within 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>TKI</keyword>
	<keyword>Mutation</keyword>
	<keyword>Liquid Biopsy</keyword>
</DOC>